Obicetrapib is an investigational cholesteryl ester transfer protein (CETP) inhibitor designed to manage lipid levels by reducing low-density lipoprotein (LDL) cholesterol while increasing high-density… Read more



Obicetrapib is an investigational cholesteryl ester transfer protein (CETP) inhibitor designed to manage lipid levels by reducing low-density lipoprotein (LDL) cholesterol while increasing high-density lipoprotein (HDL) cholesterol. This category provides essential reference standards for the active pharmaceutical ingredient, alongside related materials including synthetic process impurities, potential metabolites, and stable isotope-labelled compounds such as Obicetrapib-d5. These high-quality reference materials are critical for comprehensive impurity profiling, accurate method validation, and rigorous quality control within pharmaceutical research and development. By utilizing these precise analytical standards, laboratories can ensure the accurate identification and quantification of related substances and degradants throughout the lifecycle of the drug, supporting regulatory compliance and the maintenance of rigorous purity standards in analytical testing protocols.